GLSI

Business Context and Reporting Period

Company: Greenwich Lifesciences, Inc. (GLSI)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2026
Business Overview: GLSI is a clinical-stage biopharmaceutical company developing GLSI-100, an immunotherapy to prevent breast cancer recurrence. The company is currently conducting the Phase III Flamingo-01 clinical trial. It has no commercial revenue and relies on equity financing to fund operations.

Key Financial Metrics

Material Changes vs. Prior Period

• Increased Net Loss: Net loss for the six months ended June 30, 2026, increased by approximately $3.1 million (48%) compared to the same period in 2025. This was driven by higher clinical expenses and significant stock-based compensation.
• R&D Expense Growth: Research and development expenses rose 54% to $8.77 million, primarily due to an options grant to employees and management and increased clinical trial costs.
• Financing Activity: The company raised approximately $9.34 million in net proceeds through At-The-Market (ATM) offerings in the first half of 2026, compared to $3.10 million in the same period in 2025. The average offering price increased to $25.36 per share in 2026 from $9.95 in 2025.
• Liquidity Improvement: Cash balances increased from $6.18 million at year-end 2025 to $8.88 million at June 30, 2026, despite significant operating cash burn.

Guidance, Outlook, Risks, and Unusual Items

• Going Concern: The filing includes a "Going Concern" warning. The company has incurred net losses since inception and has negative operating cash flows. Management states that the ability to continue operations is dependent on obtaining additional capital.
• Internal Control Weaknesses: Management concluded that disclosure controls and procedures were not effective as of June 30, 2026. Material weaknesses were identified due to inadequate segregation of duties, insufficient written policies, lack of accounting systems for stock awards, and insufficient expense approval procedures.
• Related Party Transactions: Significant related party transactions exist, including deferred compensation for senior management ($673,819) and accrued unreimbursed expenses ($57,077). Management family members received cash and option compensation totaling approximately $199,000 for the six months ended June 30, 2026.
• Outlook: The company expects to continue incurring significant expenses and operating losses as it expands the Flamingo-01 trial globally and prepares for potential commercialization. No specific financial guidance was provided.
• Lock-Up Extension: In a subsequent event, the board extended the lock-up period for directors, officers, and pre-IPO investors to January 31, 2027.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $8.88 million cash balance against the current burn rate of approximately $6.6 million per six months to assess the timeline for the next capital raise.
• Internal Controls Remediation: Review the specific plan management is developing to remediate the material weaknesses in internal controls over financial reporting.
• ATM Program Capacity: Assess the remaining capacity under the ATM agreement with H. C. Wainwright and the market's ability to absorb further share issuance at current price levels.
• Clinical Trial Progress: Monitor the status of the Flamingo-01 Phase III trial, as the company's valuation is entirely dependent on the success of this single product candidate.
• Related Party Obligations: Scrutinize the nature of the $5.76 million in current liabilities, specifically the portion related to related party expenses and deferred compensation.